Correction to: The efficacy and safety profile of 2-weekly dosing of bevacizumab-containing chemotherapy for platinum-resistant recurrent ovarian cancer

Detalles Bibliográficos
Autores principales: Sekine, Masayuki, Enomoto, Takayuki, Watanabe, Yoh, Katabuchi, Hidetaka, Yaegashi, Nobuo, Aoki, Daisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520881/
https://www.ncbi.nlm.nih.gov/pubmed/34499262
http://dx.doi.org/10.1007/s10147-021-02018-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520881/
https://www.ncbi.nlm.nih.gov/pubmed/34499262
http://dx.doi.org/10.1007/s10147-021-02018-3

Ejemplares similares